Align Technology, Inc. vs Vanguard Information Technology Index Fund ETF — how do they compare? Align Technology, Inc. trades at $182.04 (market cap $12.86B), while Vanguard Information Technology Index Fund ETF trades at $117. Which is the better fit depends on your goals.
| ALGN | VGT | |
|---|---|---|
Market Cap | $12.86B | — |
Sector | Health | — |
52-Week High | $207.19 | $125.77 |
52-Week Low | $124.88 | $83.59 |
Enterprise Value | $11.92B | — |
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
VGT trades at $118.08, up 0.31% with a bullish technical signal from moving averages. The ETF shows strong institutional backing and positive media coverage highlighting its tech sector exposure and low 0.09% expense ratio. Recent news emphasizes VGT's outperformance versus QQQ and its role in AI-driven tech investments.
Outlook remains positive given tech sector momentum and AI growth catalysts, though risks include sector volatility and valuation concerns. Analyst sentiment favors VGT for broad tech diversification with competitive fees supporting long-term growth potential amid market fluctuations.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →